AllSight
Companies · QURE · Pharmaceutical Preparations

uniQure N.V. (QURE)

uniQure N.V. (QURE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

uniQure N.V. (QURE) stock — financials & valuation

Key numbers for uniQure N.V. (QURE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 40/100 — a percentile rank of uniQure N.V.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$1.6B
P / S86.8×
EV / EBITDA-7.2×
Gross margin92.5%
Operating margin-1013.1%
Net margin-1350.7%
Return on equity-77.8%
ROIC501.2%
Revenue growth30.2%
Debt / equity0.1×
Dividend yield0.0%

Is uniQure N.V. overvalued? P/S looks overvalued vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from uniQure N.V.’s own financial statements and shown as context, never as advice.

Sep 29, 2026Above the bar
uniQure Huntington’s data show durable benefit, but 48-month controls muddy the read
Sep 2, 2026BLA and MAA submitted
uniQure files AMT-130 applications on schedule, leaving four-year data as the next test
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact